MYND Life Sciences Announces $3.5 Million Share Offering Post published:April 21, 2022 Post category:Press Release
Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder Post published:April 21, 2022 Post category:Press Release
COMPASS Pathways partners with One Mind to fund Rising Star Awards for the next generation of mental health researchers Post published:April 20, 2022 Post category:Press Release
Mindset Pharma Strengthens IP Portfolio with Another New Provisional Patent Application Covering its Next-Generation DMT and 5-MeO-DMT Drug Candidate Compounds Post published:April 19, 2022 Post category:Press Release
Filament Health and Psyence Enter into Exclusive Licensing Agreement for Natural Psilocybin Products Post published:April 19, 2022 Post category:Press Release
MindMed Collaborator Dr. Matthias Liechti to Present Topline Clinical Trial Results for LSD in Anxiety Disorders at PSYCH Symposium Post published:April 14, 2022 Post category:Press Release
Numinus Wellness Inc. Reports Q2 2022 Results Post published:April 14, 2022 Post category:Press Release
Cybin Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and Inhaled DMT Post published:April 13, 2022 Post category:Press Release
Filament Health Is Issued Patent By United States Patent And Trademark Office Post published:April 13, 2022 Post category:Press Release
Awakn Life Sciences Provides Shareholder Update on Three Operational Ketamine-Assisted Therapy Clinics in the UK and Norway Post published:April 13, 2022 Post category:Press Release